Opioid addiction treatment

(a)

In general

The Assistant Secretary for Mental Health and Substance Use, acting through the Director of the Center for Substance Abuse Treatment (in this section referred to as the Assistant Secretary) shall award grants to States to expand access to clinically appropriate services for opioid abuse, dependence, or addiction.(b)

Requirements

As conditions on the receipt of a grant under this section, a State shall agree to comply with the following:(1)The grant will be administered through the head of the State’s primary agency responsible for programs and activities relating to the treatment of substance abuse.(2)The services through the grant will be evidence-based such as medication-assisted treatment for substance use disorder.(3)The services through the grant will be provided according to a physician or a clinician’s recommendation to ensure that individuals receive the optimal level of substance use disorder treatment for the amount of time that is deemed medically necessary.(4)The services through the grant will be provided exclusively to individuals—(A)who lack health insurance; or(B)whose health insurance—(i)does not cover such services; or(ii)places other barriers on the receipt of such services, such as—(I)limiting coverage of such services to a certain period of time; or(II)imposing nonquantitative treatment limitations that are more stringent than treatment limitations imposed on other medical conditions (such as a requirement to use less expensive services, like outpatient treatment, prior to more expensive, but physician-recommended services, such as inpatient or residential treatment).(5)The grant will not be used to pay or subsidize the cost of more than 60 consecutive days of opioid abuse, dependence, or addiction treatment in the case of any individual.(c)

Permissible provision of medications

In expanding access to clinically appropriate services for opioid abuse, dependence, or addiction through a grant under this section, a State may provide for the use of medications, in conjunction with other treatment, so long as the medications—(1)are lawfully marketed under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.);(2)are clinically indicated to address the abuse, dependence, or addiction; and(3)are offered consistent with consumer choice.(d)

Coordination

The Assistant Secretary shall coordinate the program under this section with the program for prevention and treatment of substance abuse under subpart II of part B of title XIX of the Public Health Service Act (42 U.S.C. 300x–21 et seq.).(e)

Evaluation; dissemination of information; technical assistance

(1)

In general

The Assistant Secretary shall—(A)require States receiving a grant under this section to report appropriate outcome measures associated with use of the grant, including any—(i)decreases in substance use;(ii)changes in retention in care;(iii)connections to the next appropriate level of care;(iv)decreases in involvement with criminal justice activities; and(v)other outcome data as appropriate;(B)require States receiving a grant under this section to report data on individuals’ length of time under clinically appropriate addiction treatment, and the use of medication-assisted treatment;(C)evaluate the activities supported by grants under this section;(D)submit to the Congress and the Secretary, and make publicly available on the internet site of the Substance Abuse and Mental Health Services Administration, information about the results of such evaluation; and(E)offer technical assistance to States receiving a grant under this section regarding activities funded through the grant.(2)

Use of certain funds

Of the funds appropriated to carry out this section for any fiscal year, 5 percent shall be available to carry out activities under this subsection.